Tackling Undruggable Cancer Targets using Chemoproteomic Platforms

使用化学蛋白质组学平台应对无法成药的癌症靶标

• 批准号: 10518755
• 负责人: Daniel Nomura
• 金额: $ 92.82万
• 依托单位: UNIVERSITY OF CALIFORNIA BERKELEY
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-08-01 至 2029-07-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10518755
• 关键词: Antineoplastic Agents; Binding; Development; Ligands; Malignant Neoplasms; Modality; Pharmacology; Proteins; Proteome; Research; Therapeutic; chemoproteomics; drug discovery; innovative technologies; next generation; novel therapeutics; targeted treatment

One of the biggest challenges facing cancer drug discovery is that >90 % of the proteome is currently considered “undruggable” because most proteins do not possess known binding pockets or “ligandable hotspots” that can be pharmacologically and functionally targeted for therapeutic benefit 1. Tackling the undruggable proteome requires the development of innovative technologies for ligand discovery AND the discovery of novel therapeutic modalities to functionally manipulate the undruggable proteome for therapeutic benefit. The Nomura Research Group is focused on reimagining druggability by advancing and applying chemoproteomic platforms to tackle the undruggable proteome, towards developing next-generation therapies and therapeutic modalities for cancer.

癌症药物发现面临的最大挑战之一是，90%的蛋白质组是